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The association of coronary arterial calcification with cardiovascular morbidity and mortality
is well-recognized. Lower limb arterial calcification (LLAC) is common in PAD but its impact
on subsequent health is poorly described. We aimed to determine the association between
a LLAC score and subsequent cardiovascular events in patients with symptomatic periph-
eral arterial disease (PAD).
Methods
LLAC scoring, and the established Bollinger score, were derived from a database of unen-
hanced CT scans, from patients presenting with symptomatic PAD. We determined the
association between these scores outcomes. The primary outcome was combined cardiac
mortality and morbidity (CM/M) with a secondary outcome of all-cause mortality.
Results
220 patients (66% male; median age 69 years) were included with follow-up for a median 46
[IQR 31–64] months. Median total LLAC scores were higher in those patients suffering a pri-
mary outcome (6831 vs. 1652; p = 0.012). Diabetes mellitus (p = 0.039), ischaemic heart
disease (p = 0.028), chronic kidney disease (p = 0.026) and all-cause mortality (p = 0.012)
were more common in patients in the highest quartile of LLAC scores. The area under the
curve of the receiver operator curve for the LLAC score was greater (0.929: 95% CI [0.884–
0.974]) than for the Bollinger score (0.824: 95% CI [0.758–0.890]) for the primary outcome.
A LLAC score 4400 had the best diagnostic accuracy to determine the outcome measure.
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Conclusion
This is the largest study to investigate links between lower limb arterial calcification and car-
diovascular events in symptomatic PAD. We describe a straightforward, reproducible, CT-
derived measure of calcification—the LLAC score.
Introduction
Peripheral arterial disease is an increasingly prevalent condition in both high and medium /
low income countries [1, 2], associated with significant risk of long-term cardiovascular mor-
bidity and mortality [3]. Thus, beyond treatment of symptoms, there is a growing need for
detailed risk stratification and prognostication to allow appropriate patient-focused preventa-
tive strategies to impact upon the broader significant cardiovascular risks in these patients.
Vascular calcification is characteristic of atherosclerosis [4]. An active process, in pre-clini-
cal models, inflammatory macrophage activity is seen to precede early osteogenesis [5]. Micro-
deposits may then coalesce into larger deposits of calcium [6].
Calcification has variable effects on the arterial tree; large calcified plaques can cause flow-
limiting stenoses, whereas microcalcification may increase the chance of plaque rupture and
its associated clinical sequelae [7]. In clinical practice, coronary calcium scoring using com-
puted tomography (CT) serves as a marker for the extent of atherosclerosis and is used to risk-
stratify patients in terms of coronary heart disease, providing better discrimination than clini-
cal risk factors alone [8].
CT is used to delineate arterial anatomy in PAD. Only one study has investigated, however,
the prognostic implications of lower limb arterial calcification in patients with symptomatic
PAD. Huang et al, recruited a small number of East Asian subjects (n = 82) and linked periph-
eral vascular calcification with amputation and mortality during follow-up [9]. In larger stud-
ies, associations between calcium scores and disease severity have been observed, but no
follow-up undertaken [10,11].
The primary aim of this CT-based study was to test whether a new score of lower limb arte-
rial calcification, the LLAC score, could predict cardiovascular mortality and morbidity in a
large, consecutive, well-characterised cohort of symptomatic patients with PAD.
Methods
Patient identification
This was a retrospective, observational, single-centre study consisting of consecutive patients
with symptomatic lower limb PAD presenting to Addenbrooke’s Hospital, Cambridge, U.K.
between January 2009 and January 2013. Only patients undergoing lower limb CT angiogra-
phy were included. This study was registered with the local Addenbrooke’s Hospital Institu-
tional Audit department—to ensure all data collection was in line with local committee ethical
standards. Patients were de-identified and analysed anonymously. All had evidence of at least
one stenosis of>50% in the lower limb arterial tree (from the aorta at the level of the lower-
most renal artery distally). Subjects with prior lower extremity amputation or poor-quality CT
imaging were excluded. Follow-up data was available for a median of 46 months (31–64). Mor-
tality and morbidity data were obtained from hospital medical records, death certificates and
community medical notes.
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Patient demographics, past medical history and medication usage were determined from
the hospital electronic record system. Ischaemic heart disease was defined as a clinical diagno-
sis of angina, a prescription of anti-anginal drugs or a history of myocardial infarction or a cor-
onary revascularization procedure. Cerebrovascular disease / transient ischaemic attack
(CVA/TIA) was determined as a previous history of a cerebral event with associated neurol-
ogy. Chronic kidney disease was defined as an estimated glomerular filtration rate 59 ml/
min/1.73m2) (Supporting information S1 File).
The primary end-point was combined cardiac mortality and morbidity (CM/M) within the
follow up period with a secondary endpoint of all-cause mortality. Cardiac mortality was
defined as death with documented evidence of acute myocardial infarction (MI). Cardiac mor-
bidity was defined as a hospital admission with either (i) typical cardiac chest pain with ischae-
mic ECG changes or (ii) typical chest pain with elevated cardiac enzymes or (iii) a discharge
coding of a coronary event. Events were classified by the attending medical teams (in-hospital
events) or pathologists at post mortem (community event). Where hospital data was missing,
data was sourced either from the primary care team or from the death certificate.
The further vascular procedure that some patients went on to have include a variety of open
and endovascular interventions, including angioplasty, stent insertion, arterial bypass and
amputation.
Measurement of arterial calcification using the LLAC score
Patients underwent lower limb CT imaging on a 64-slice CT scanner (Siemens Somatom Defi-
nition AS), using standard clinical protocols. Briefly, scans were performed using helical acqui-
sition with kV = 120, mA = 200 with a field of view of 350–380 mm yielding typical spatial
resolution 0.7x0.7x3.0 mm3. From acquired raw data, the scan was reconstructed in 3-mm
slices. The average radiation dose was 4.3 mSv per patient. Image analysis was performed on
an Apple Macintosh computer (Apple Inc, Cupertino, CA, US) using the open-source
DICOM viewer (v4, OsiriX Imaging Software, Pixeo SARL).
Calcification data was derived from unenhanced CT images (Fig 1). Using the freely avail-
able ‘Calcium Scoring’ plug-in, vascular calcification (based on an attenuation threshold of 130
Hounsfield Units in 3 contiguous voxels, after the method of Agatston [12]) was analyzed on
consecutive transaxial slices along the length of the arterial segment, as previously described
[13].
For the purpose of this study, the lower limb arterial tree was defined as from the infrarenal
aorta to the ankle in both legs, divided into three anatomical segments the aorto-iliac (AI) seg-
ment (lower most renal artery to the distal aspect of the iliac artery), the femoro-popliteal (FP)
segment (common femoral artery to the below knee popliteal artery) and the crural segment
(the tibioperoneal trunk and individual crural vessels down to the ankle joint).
The total LLAC score for each patient consisted of the sum of the LLAC score of both legs.
Individual leg LLAC scores comprised of the sum of the AI, FP and crural segmental LLAC
scores.
Segmental scores were calculated by adding the segmental scores from each leg. For exam-
ple, the total FP segment score for an individual patient was the FP segment score of the right
leg plus the FP segment score of the left leg.
Measurement of atherosclerosis severity and extent using the Bollinger
score
Peripheral atherosclerosis can be described using the Bollinger scoring method, as in previous
studies of lower limb arterial disease [14]. The score has a high level of inter-observer
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agreement [15,16]. The score is based on the number and presence of stenoses and occlusions
at angiography, originally digital subtraction angiography, but also validated using CT angiog-
raphy [17].
Each of the arterial segments (division of which is described above) was scored according to
the severity of disease. Four severities of disease are recognised by the Bollinger method: occlu-
sion of the lumen, stenosis >50% of the luminal diameter, stenosis 25–49% of the luminal
diameter and plaques affecting<25% of the luminal diameter.
Fig 1. Arterial calcification. Unenhanced multi-sliced computed tomography images of arterial calcification (A)
circumferential calcification of the distal abdominal aorta (B) calcification of both distal superficial femoral arteries at the
level of the adductor hiatus with evidence of significant intraluminal stenotic plaque disease. Arrows identify areas of
calcification.
https://doi.org/10.1371/journal.pone.0182952.g001
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Each type of lesion was then further characterized by its extent within the artery -either a
single lesion, multiple lesions affecting less than half of the arterial segment or multiple lesions
affecting greater than half of the segment.
Again, total Bollinger scores were cumulative scores from both limbs. Segmental scores
were calculated cumulatively, as per LLAC scores (see above).
LLAC and Bollinger scoring reproducibility
Inter-observer reproducibility of the LLAC and Bollinger scores was determined in 10 patients
by two experienced readers (MC and GM). Intra-observer reproducibility was determined for
both the LLAC and Bollinger scores by a reader blinded to patient demographics (MC). Fifteen
datasets were scored on two occasions 7 days apart.
Statistical methods
Statistical analyses were performed using SPSS (version 22, IBM, Armonk, NY, USA). The
normality of continuous variables was checked using the Kolmogorov-Smirnov test; this dem-
onstrated that both LLAC and Bollinger score were non-parametric. Variables are expressed as
mean ± standard deviation, median (Quartile 1-Quartile 3) or n (%), as appropriate. Correla-
tions between the LLAC and Bollinger scores were tested using Spearman’s rank correlation
coefficient. Binary multivariate logistic regression analysis was performed to determine the
individual parameters correlated with LLAC and Bollinger score. Given the non-parametric
distributions, comparison of data sets across different cohorts was performed using the Krus-
kal-Wallis test. Receiver-operator characteristic (ROC) curves were generated for both LLAC
and Bollinger scores against the primary outcome. Intra- and inter-observer reproducibility
was tested using intra-class correlation coefficients (ICC). p-values of<0.05 were considered
significant.
Results
Of 386 consecutive patients initially assessed, 220 met the inclusion criteria for the CT-based
study (Fig 2). The median age of those included was 69 (63–88) years; 146 (66%) were male.
Demographic data are shown in Table 1. 189 (86%) patients were smokers, 79 (36%) had IHD
and 43 (20%) prior cerebrovascular disease. 203 patients (92%) were taking an anti-platelet
agent and 187 (85%) were receiving statin therapy.
With regards to the primary outcome during follow-up, there were 5 fatal spontaneous
MIs. 3 subjects had ST-elevation myocardial infarctions (STEMI) that resulted in death; the
remaining 2 had evidence of acute myocardial infarction discovered at post mortem. 13
patients had non-fatal STEMI, 10 patients non-fatal non-ST elevation myocardial infarctions
and 4 patients had a discharge coding of ‘acute coronary event’ with elevated cardiac enzymes.
With regards to the secondary outcome of all-cause mortality, there were 5 deaths due to
cardiac causes, 4 deaths due to complications of disseminated malignancy and 3 patients died
of pneumonia.
The median LLAC score for all patients was 2060 (182–5069). Diabetes mellitus (p = 0.039),
chronic kidney disease stage 3 (p = 0.026) and a history of IHD (p = 0.028) were more com-
mon in those with LLAC scores in the fourth quartile (Table 2).
Nearly all (98%) of the adverse events (both primary and secondary outcomes) occurred in
patients whose total LLAC score was in the highest quartile at baseline. Patients had signifi-
cantly higher LLAC score when looking at the primary outcome (6831 vs. 1652, p = 0.012), as
well as secondary outcome (8273 vs. 854, p<0.001). Assessment of LLAC score with primary
and secondary outcomes were analysed using the total LLAC score (Table 3).
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The median Bollinger score for all patients was 177 (116–258). Again, diabetes mellitus
(p = 0.036) and previous history of IHD (p = 0.028) were more common in patients in the
fourth quartile (Table 4). Similarly, to the LLAC score, more than 90% of adverse events
occurred in patients in the highest Bollinger score quartile (Table 5). Again, patients who had
Fig 2. Study profile.
https://doi.org/10.1371/journal.pone.0182952.g002
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primary and secondary outcomes had significantly higher segmental Bollinger than those who
did not.
There was a very strongly positive correlation between total LLAC and Bollinger scores
(r = 0.936; p<0.001; Fig 3).
Table 1. Baseline demographics.
(n = 220)
Age, years 69 (63–88)
Male 146 (66)
Caucasian 198 (90)
Medical History at time of scan
Ischaemic Heart Disease 59 (36)
Hypertension 157 (71)
Diabetes Mellitus 51 (23)
Cerebrovascular disease / transient ischaemic attack 43 (20)
Chronic kidney disease 37 (17)
Hypercholesterolaemia 164 (75)
Current smoker 189 (86)
Medications
Antiplatelet agent 203 (92)
Statin use 187 (85)
Values are median (quartile 1 –quartile 3) or n (%)
https://doi.org/10.1371/journal.pone.0182952.t001
Table 2. Baseline characteristic and clinical outcomes by total LLAC score quartiles.
Q1 Q2 Q3 Q4 p value
(n = 55) (n = 55) (n = 55) (n = 55)
Age 67 (63–71) 63 (61–72) 70 (64–75) 72 (63–76) 0.875
Male 34 33 40 39 0.762
Ischaemic Heart Disease 8 12 17 22 *0.028
Hypertension 28 42 36 51 0.078
Diabetes Mellitus 2 3 21 25 *0.039
CVA/TIA 8 11 10 14 0.546
Chronic kidney disease 1 4 15 17 *0.026
Current smoker 45 53 42 49 0.543
Antiplatelet 42 55 52 54 0.765
Statin use 34 54 46 53 0.454
Length of follow-up, months 41 (29–57) 49 (34–68) 49 (31–66) 46 (32–60) 0.765
CM/M 0 0 1 31 *< 0.001
All-cause mortality 0 0 0 12 *0.012
Values are n or median [quartile 1-quartile 3].
LLAC = lower limb arterial calcification; Q = quartile; CM/M = cardiac mortality and morbidity
CVA/TIA = cerebrovascular disease/transient ischaemic attack
CM/M = combined cardiac mortality and morbidity;
*p<0.05 taken to be statistically significant.
https://doi.org/10.1371/journal.pone.0182952.t002
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ROC curves were generated to test the power of both scores to predict the primary outcome
(Fig 4). We found that the area under the curve for the LLAC score was greater (0.929: 95% CI
[0.884–0.974], p<0.001) than for the Bollinger score (0.824: 95% CI [0.758–0.890], p<0.001).
Furthermore, a cut-off LLAC score of 4400 had a sensitivity of 84.4%, specificity of 83.5%, pos-
itive predictive value (PPV) of 46%, and negative predictive value (NPV) of 97% to predict the
primary outcome. Applied to the Bollinger score, the cut-off value was 260.5 (sensitivity
71.9%, specificity 84.6%, NPV 92%, PPV 31%).
Excellent inter- and intra-observer reliability scores were demonstrated for both LLAC
(ICC 0.99 and 0.98, respectively) and Bollinger scores (ICC 0.96 and 0.92, respectively).
Discussion
This is the largest CT-specific study to investigate links between lower limb arterial calcifica-
tion, cardiovascular mortality and morbidity and all-cause mortality in patients with symp-
tomatic PAD.
PAD patients remain at very high risk of cardiovascular events [3]. Here, despite a more
widespread use of secondary preventative therapy, the primary outcome was seen in 15% over
a median follow-up of 46 months. We recognise that the patients selected in this study may
represent the more severe end of the spectrum of patients with PAD, in view of the fact that
Table 3. Total and segments LLAC scores in patients with and without cardiovascular events during
follow-up.
Patients LLAC Score p value
Total Lower Limb
CM/M Yes 32 6831 [6564–7713] *0.012
CM/M No 188 1652 [162–2699]
All-cause mortality Yes 12 8273 [7827–9144] *<0.001
All-cause mortality No 208 1842 [173–4452]
AI Region
CM/M Yes 32 4557 [2383–4814] *0.012
CM/M No 188 854 [567–2453]
All-cause mortality Yes 12 5761 [1404–6796] *< 0.001
All-cause mortality No 208 869 [678–2345]
FP Region
CM/M Yes 32 1150 [800–1580] *0.017
CM/M No 188 511 [345–2319]
All-cause mortality Yes 12 1849 [780–2113] *0.013
All-cause mortality No 208 572 [123–2675]
Crural Region
CM/M Yes 32 1125 [483–1314] *< 0.001
CM/M No 188 287 [165–872]
All-cause mortality Yes 12 663 [404–896] *0.042
All-cause mortality No 208 401 [347–976]
Values are n or median [quartile 1- quartile 3]
LLAC = lower limb arterial calcium; CM/M = combined cardiac mortality and morbidity; AI = Aortoiliac;
FP = Femoropopliteal
*p<0.05 taken to be statistically significant.
https://doi.org/10.1371/journal.pone.0182952.t003
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Table 4. Baseline characteristic and clinical outcomes by Bollinger score quartiles.
Q1 Q2 Q3 Q4 p value
(n = 55) (n = 55) (n = 55) (n = 55)
Age 65 (63–74) 62 (61–71) 78 (69–88) 74 (68–86) 0.768
Male 47 42 23 34 0.654
Ischaemic Heart Disease 8 11 19 21 *0.028
Hypertension 27 48 39 43 0.453
Diabetes Mellitus 3 5 12 37 *0.036
CVA/TIA 7 14 8 14 0.343
Chronic kidney disease 7 9 8 13 0.675
Current smoker 46 47 42 54 0.765
Antiplatelet agent 55 43 50 55 0.768
Statin use 40 54 45 48 0.765
Length of follow-up, months 41 (29–57) 49 (34–68) 49 (31–66) 46 (32–60) 0.765
CM/M 0 0 1 31 *< 0.001
All-cause mortality 0 0 0 12 *0.012
Values are n or median [interquartile range]
CVA/TIA = cerebrovascular disease/transient ischaemic attack
CM/M = combined cardiac mortality and morbidity;
*p<0.05 statistically significant.
https://doi.org/10.1371/journal.pone.0182952.t004
Table 5. Total and segmental Bollinger scores in patients with and without cardiovascular events dur-
ing follow-up.
Patients Bollinger scores p value
Total Lower Limb
CM/M Yes 32 276 (184–300) *0.032
CM/M No 188 164 (107–235)
All-cause mortality Yes 12 296 (282–300) *0.047
All-cause mortality No 208 171 (112–245)
AI Region
CM/M Yes 32 34 (26–67) 0.067
CM/M No 188 48 (17–56)
All-cause mortality Yes 12 53 (41–76) *0.043
All-cause mortality No 208 36 (15–49)
FP Region
CM/M Yes 32 111 [65–119] *0.026
CM/M No 188 49 [31–115]
All-cause mortality Yes 12 114 [71–123] *0.021
All-cause mortality No 208 52 [32–126]
Crural Region
CM/M Yes 32 131 [73–158] *0.031
CM/M No 188 67 [49–177]
All-cause mortality Yes 12 129 [76–161] *0.048
All-cause mortality No 208 83 [65–176]
Values are n or median [quartile 1- quartile 3]
CM/M = combined cardiac mortality and morbidity; FP = Femoropopliteal
*p<0.05 taken to be statistically significant.
https://doi.org/10.1371/journal.pone.0182952.t005
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they have required lower limb CT imaging yet, beyond palliation of symptoms, reducing these
events remains an unmet clinical need.
The presence of lower limb atherosclerosis has long been recognised as a powerful predictor
of cardiovascular outcome [18]. The ankle-brachial pressure index (ABPI) has been shown to
predict outcome in a number of epidemiological studies [19]. Yet ABPI measurement is sub-
ject to considerable variability and there is a lack of consensus about the optimal method to
measure it [20].
The Bollinger score provides an alternative well-validated descriptor of peripheral athero-
sclerosis [16]. Though offering improved inter-observer reproducibility as compared to the
ABPI [22]; it is essentially lumenography. There were previously no data linking the Bollinger
score to subsequent cardiovascular events.
Atherosclerosis is a systemic inflammatory disease [21], with calcification its hallmark.
There is increasing interest in the implications of non-coronary arterial calcification visible on
CT [22,23]. Given the increasing use of ionizing radiation in medicine [24], it would be advan-
tageous to be able to use non-coronary vascular imaging to risk-stratify individuals for coro-
nary events. Aortic calcification predicts all-cause mortality [25] and cardiovascular events,
though not as strongly as coronary artery calcium [26]. In a large retrospective of mostly
asymptomatic subjects, iliac artery calcification had greater predictive value for cardiovascular
Fig 3. Correlation between total LLAC and Bollinger scores in patients with symptomatic peripheral arterial
disease. Statistical analysis performed using Spearman’s rank correlation coefficient. p<0.05 taken to be statistically
significant.
https://doi.org/10.1371/journal.pone.0182952.g003
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events than carotid or aortic calcification [27]. The prognostic implications of vascular calcifi-
cation in those with symptomatic PAD has not been previously studied.
Herein, we describe a straightforward, reproducible, measure of peripheral arterial calcifi-
cation—the LLAC score, information derived from a clinically-indicated peripheral CT scan.
In addition to a significant association with prior ischaemic heart disease and diabetes, the
LLAC score, not unexpectedly, was higher in those with renal impairment, a known driver of
arterial calcification [28]. The next challenge is to adapt such calcium scoring to other imaging
modalities, specifically lower limb arterial duplex. Yet, ease of access and validity of the imag-
ing techniques means that CT angiography is still widely used in assessment of the lower limb
Fig 4. Receiver-operator curves for total LLAC and Bollinger scores and the primary outcome of cardiac mortality
and morbidity. AUC for the LLAC score was 0.929 (95% CI 0.884–0.974), p< 0.001 AUC for the Bollinger score 0.824
(95% CI 0.758–0.890), p<0.001 ROC = receiver-operator curve; LLAC = lower limb arterial calcification; AUC = area under
the curve; CI = confidence interval.
https://doi.org/10.1371/journal.pone.0182952.g004
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arterial tree and other vascular beds, specifically with regard to coronary artery calcium
scoring.
Calcification can be a marker of ongoing inflammation—and its link in this study with
increased mortality risk may translate to increased levels of inflammatory disease within other
arterial beds.
Interestingly, LLAC and Bollinger scores were very highly correlated. In the coronary arter-
ies, the relationship between luminal stenosis and calcium scores is rather modest [29].
Though shear stresses and the composition of the arterial wall may differ, intravascular ultra-
sound suggests that coronary and peripheral plaques do not significantly differ with respect to
the percentage of dense calcification [30]. More likely, the observed correlation relates to the
differing modes of presentation; patients with symptomatic PAD more often presenting with
the haemodynamic consequences of mostly stable calcified lesions.
Non-coronary calcification has previously been shown to have a linear relationship with
mortality [7,8]. Though there were a modest number of clinical events, virtually all events
occurred in those with the highest quartile of both LLAC and Bollinger scores. 71% of patients
had a previous history of IHD. The combination of PAD and coronary disease (i.e. advanced
atherosclerosis) is known to be associated with poorer long-term prognosis [31,32].
The median time from scan to primary outcome in quartile 4 (Table 2) was 21 (16–32)
months. Furthermore, 35% (19/55) of patients suffered from intermittent claudication. The
value of the LLAC score here is evident; there is a clear interval in time between outcome and
scan, in which patients can be optimised for risk reduction. Not only patients with a preceding
history of IHD suffer from poor cardiovascular outcomes—indeed, only 22 patients of the 31
patients that met the primary outcome had an existing history of IHD.
How might these risks be reduced? Clearly, optimal secondary preventative therapy is cru-
cial. Guideline-directed risk factor management is associated with improved outcomes [33].
More speculatively, an LLAC score in the highest quartile may identify some individuals with
either significant undiagnosed coronary disease or a group for whom medical management of
coronary disease is perhaps insufficient. Thoracic aortic calcification is positively correlated
with the extent of myocardial ischaemia on perfusion scintigraphy [34]; coronary revasculari-
sation in patients with extensive ischaemia may improve outcomes [35]. Further research into
the relationship between peripheral calcification, coronary artery disease, the burden of myo-
cardial ischaemia and medium-term events is required.
Limitations
There are several limitations to this study. The clinical, imaging and events data were collected
retrospectively but do represent consecutive patients that passed through our hospital. Our
departmental protocol is to use duplex ultrasound imaging as first-line in symptomatic PAD
patients. The biggest limitation is that CT imaging is typically reserved for patients requiring a
more complex intervention (endovascular or surgical). This will have resulted in a degree of
selection bias. It is clear that there is a large cohort of patients not included in the analysis due
to the use of differing imaging modalities, specifically lower limb arterial duplex. The majority
of patients (90%) in this study were white Caucasian males in keeping with our local popula-
tion; this may also limit the generality of our results.
Conclusion
Patients with symptomatic peripheral arterial disease are amongst those at highest-risk for cor-
onary events. There is increasing interest in the implications of non-coronary vascular calcifi-
cation. We describe a CT-based lower limb arterial calcification (LLAC) score, derived from
LLAC scores in PAD predict poor outcomes
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clinically-indicated CT imaging. Those patients with symptomatic PAD and the highest quar-
tile of LLAC scores are more likely to be diabetic, have renal impairment, and/or a history of
ischaemic heart disease. Furthermore, extensive calcification in such patients is associated with
cardiac mortality and morbidity during follow-up; likely it serves as a marker for advanced sys-
temic atherosclerosis. Whilst prospective validation of these findings is warranted, these data
reinforce the need for aggressive medical therapy and new strategies to improve cardiovascular
outcomes in this high-risk group.
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